A reprogramming-based strategy for drug repositioning in patients with mitochondrial DNA-associated Leigh syndrome

Bidragets beskrivning

Mitochondrial DNA (mtDNA)-associated Leigh syndrome (MILS) is a severe early-onset brain disease affecting 1/100,000 newborns, with no treatments. Drug discovery is challenged by e.g. lack of mtDNA editing methods for transgenic models. Our consortium will employ reprogramming derived MILS neural cells in a large-scale market drug screen, for which we have proof-of-concept: we identified specific enzyme inhibitors as a potential therapy for MILS, with preliminary promising effects in compassionate treatment trials. Here, we extend this approach to a library of repurposable compounds, and validate hits by multi-omics analysis of e.g. neural progenitor and neuronal lines. Our consortium will identify drugs suited for repositioning in MILS, laying the foundation for a multi-national clinical trial and a concrete path towards a cure. We will establish a paradigmatic pipeline for reprogramming-driven drug discovery for rare neurological disorders.
Visa mer

Startår

2021

Slutår

2024

Beviljade finansiering

Anu Wartiovaara Orcid -palvelun logo
273 292 €

Finansiär

Finlands Akademi

Typ av finansiering

Kansainvälinen yhteisrahoitteinen ohjelma

Övriga uppgifter

Finansieringsbeslutets nummer

344744

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Biolääketieteet

Identifierade teman

brain, neuroscience